Shalwitz, Robert,Hartman, Charlotte,Buch, Akshay,Shalwitz, Isaiah,Janusz, John,Gardner, Joseph
申请号：
NZ75390514
公开号：
NZ753905A
申请日:
2014.06.04
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS. Wherein the dosing regimen is an oral daily dose of 150 to 750 mg of the compound { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, so as to raise the total iron binding capacity (TIBC) relative to a baseline TIBC without significantly increasing the serum iron level relative to the baseline serum iron level.
